Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction
NCT ID: NCT04141800
Last Updated: 2021-05-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
565 participants
Study Classification
OBSERVATIONAL
Study Start Date
2019-04-30
Study Completion Date
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Participant centres and researchers:
20 National Public Health System hospitals. Cardiology specialist physicians
* Clinical Research Ethics Committee (CREC):
Hospital 12 de Octubre, Madrid
\- Main goal: To estimate prevalence and, in medium term basis (12 months), incidence of hyperkalaemia in heart failure (HF) outpatients with reduced ejection fraction (REF) and its relationship with non-optimal HF therapy and clinical outcomes (mortality and hospital admission).
\- Study design: National multicentric prospective observational study that includes 12 months follow-up of consecutive cases of HF outpatients with REF. Inclusion baseline visit and follow -up visits at 12 months will be scheduled for collecting clinical and blood sample data of patients.
\- Study population: The expected number of patients recruited in 20 Spanish research centres is 600.
20 National Public Health System hospitals. Cardiology specialist physicians
* Clinical Research Ethics Committee (CREC):
Hospital 12 de Octubre, Madrid
\- Main goal: To estimate prevalence and, in medium term basis (12 months), incidence of hyperkalaemia in heart failure (HF) outpatients with reduced ejection fraction (REF) and its relationship with non-optimal HF therapy and clinical outcomes (mortality and hospital admission).
\- Study design: National multicentric prospective observational study that includes 12 months follow-up of consecutive cases of HF outpatients with REF. Inclusion baseline visit and follow -up visits at 12 months will be scheduled for collecting clinical and blood sample data of patients.
\- Study population: The expected number of patients recruited in 20 Spanish research centres is 600.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
NCT05408039
Hyperkalemia
COMPLETED
Treatment of Hypertension in Primary Care in Spain
NCT00868881
Hypertension
COMPLETED
The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study
NCT04190420
Hypertension
Heart Failure
Hypertensive Heart Disease
+1 more
ENROLLING_BY_INVITATION
Prospective Study on Primary Aldosteronism in Resistant Hypertension
NCT04213963
Resistant Hypertension
Primary Aldosteronism
Refractory Hypertension
+3 more
RECRUITING
Prevalence of Primary Aldosteronism Among Hypertensive Patients With Atrial Arythmia
NCT04115280
Primary Aldosteronism
Atrial Fibrillation
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PARTICIPANT CENTRES AND RESEARCHERS: 20 National Public Health System hospitals. Cardiology specialist physicians
MAIN GOAL: To estimate prevalence and, in medium term basis (12 months), incidence of hyperkalaemia in heart failure (HF) outpatients with reduced ejection fraction (REF) and its relationship with non-optimal HF therapy and clinical outcomes (mortality and hospital admission).
SPECIFIC GOALS:
1. -Estimating Hyperkalaemia prevalence in these patients.
2. -Assessing the role of hyperkalaemia with the use of non-optimal therapy doses.
3. -Estimating 12 months hyperkalaemia incidence on these patients and describing the severity of the episodes.
4. -Estimating incidence of HF hospital admission and/or death in these patients on a medium term basis (12 months) and its association with existence of hyperkalaemia during follow up.
5. -Assessing hyperkalaemia risk during follow-up in relation with the existence of diabetes and/or renal failure (RF) at baseline visit.
STUDY DESIGN National multicentric prospective observational study that includes 12 months follow-up of consecutive cases of HF outpatients with REF. Inclusion baseline visit and follow -up visit at 12 months will be scheduled for collecting clinical and blood sample data of patients.
The study will be performed in ordinary conditions of clinical practice; no additional procedures or interventions will be performed. Patients will be selected in cardiology outpatient clinics of 20 Spanish centres, including the first 30 patients meeting inclusion and exclusion criteria. All patients will undergo the common studies according to usual clinical practice and at least both, potassium and renal creatinine clearance values will be collected.
To respond to the main objective, prevalence of hyperkalaemia at baseline will be determined as well as the appearance of new hyperkalaemia cases in the follow up of patients that had normal potassium levels at baseline visit; their relationship with outcomes of interest will also be determined
STUDY POPULATION:
The expected number of patients recruited in 20 Spanish research centres is 600.
CONSIDERATIONS ABOUT SIMPLE SIZE:
Assuming a 10% risk of outcomes (mortality or HF hospital admission) among the exposed (hyperkalaemia), 2.5% among the non-exposed and a 7:1 non-exposed/exposed ratio, 73 exposed and 511 non-exposed patients should be included to have a 80% power to detect these differences with a 95% confidence level. The recruitment goal is set at 600 patients.
This sample size allows a precision of ±2,4%, assuming a prevalence of hyperkalaemia at baseline of 10% and with a 95% confidence level. Furthermore, assuming 5% hyperkalaemia cumulative incidence through follow-up among hyperkalaemia-free patients at baseline, the proposed sample size, allows a precision of±1,8% with a 95% confidence level.
SELECTION OF CENTRES The number of participant centres throughout Spain will be 20 and a cardiologist will be the principal investigator at every centre. The centres have been selected either among those with excellence-certified HF units, included in CiberCV Consortium or with good performance in previous similar registries; this selection is not random, but based on interest and high performance criteria in the field of HF
VARIABLES AND CRF:
The main outcome variables are:
1. \- Hyperkalaemia. Serum Potassium (K+) will be measured in baseline and follow-up visits, but also if there is any intermediate hospital admission. All available potassium measurements during follow-up will be reviewed and values of hyperkalaemia identified. Hyperkalaemia will be considered with (K+) Values \> 5,4 mEq/L
2. \- Proportion of patients using drugs with proven efficacy for HF with REF -but also linked with hyperkalaemia- (ACEIs/ARB-II/ARNI and MRAs) and proportion of patients with use of optimal doses (based on current ESC heart failure guidelines2) of the same drugs; reason for not using them (or not receiving optimal doses) will be registered. Proportion of patients in the following categories will also be computed:
* No ACEi/ARB/ARNI or at less than target dose and no MRA
* ACEi/ARB/ARNI at target dose and no MRA
* ACEi/ARB/ARNI at target dose and MRA at less than target dose
* ACEi/ARB/ARNI at target dose and MRA at target dose
3. \- Hospital admissions during follow-up and main cause for them. Outcomes considered will include HF admissions caused by hyperkalaemia and related events. Outcome Serum (K+) values will be also registered.
4. \- Mortality and cause. HF (and hyperkalaemia) hospital admissions and mortality will be independently considered as outcomes; joint outcome incidence of both will be also calculated.
STUDY DEVELOPMENT:
Every participating centre will include from inclusion date the first 30 heart failure outpatients who fulfil the inclusion criteria and none of the exclusion ones. The excluded patients will be also registered, pointing out the reason of exclusion. A follow-up and final visit will be scheduled after 12 months for collecting all the variables the study requires. Hospitalisation data since inclusion visit will be also collected, together with the information of blood sample test performed in such period for detecting hyperkalaemia episodes. Mortality data will include date and cause, where possible. If follow-up visit cannot be conducted, the reason for it will be registered. The envisaged length of the study is 24 months since approval date.
DATA COLLECTION:
Consecutively, every researcher will handle and explain the information sheet to the patients that might fulfil de inclusion criteria (and do not present any exclusion criteria) and will ask them to sign the informed consent. Researchers must warrant the accuracy and completion of the data collected for the study. Data registered at CRF should be consistent with source documents used for their collection.
DATA MANAGEMENT:
Data will be collected during initial and follow-up visits and they will be integrated into a unique data base of the web platform. Researchers are responsible of the information included in the database and will access by means of personal login and password. The online platform will include ranges and rules to minimize errors in data registering.
PLAN FOR DATA ANALYSIS Hyperkalaemia prevalence at basal visit and the rate of patients who do not receive and/or reach optimal doses of drugs of interest (ACIEs, ARB-II, MRAs) will be estimated and their corresponding 95% confidence intervals computed. The reason for not receiving and/or reaching optimal doses of drugs will be described, especially if it is due to hyperkalaemia.
For those patients who do not present hyperkalaemia at baseline, 12 month hyperkalaemia cumulative incidence (95% confidence interval) will be estimated; also it will be estimated the proportion of patients who have to modify their therapy due to hyperkalaemia.
The number of episodes of hyperkalaemia during follow-up in relation to the number of patients will be estimated and their severity and the therapy changes that induced described. Also 12 months cumulative incidence of clinical outcomes will be estimated: hospitalisation due to HF or to, hyperkalaemia (and related events) and mortality, considered as individual and composite outcomes. The association between hyperkalaemia and occurrence of outcomes will be analyses and also adjusted using potential confounding factors by means of logistic regression models
The quantitative variables will be generally described using either the mean and the standard deviation or the median and interquartile range according them following or not a normal distribution. When comparing groups, t-student test will be used for continuous variables and chi-share test for qualitative ones.
Both, intermediate and final analysis, are planned to be carried out after baseline-visit closure and at the end of follow up (12 months).
MAIN GOAL: To estimate prevalence and, in medium term basis (12 months), incidence of hyperkalaemia in heart failure (HF) outpatients with reduced ejection fraction (REF) and its relationship with non-optimal HF therapy and clinical outcomes (mortality and hospital admission).
SPECIFIC GOALS:
1. -Estimating Hyperkalaemia prevalence in these patients.
2. -Assessing the role of hyperkalaemia with the use of non-optimal therapy doses.
3. -Estimating 12 months hyperkalaemia incidence on these patients and describing the severity of the episodes.
4. -Estimating incidence of HF hospital admission and/or death in these patients on a medium term basis (12 months) and its association with existence of hyperkalaemia during follow up.
5. -Assessing hyperkalaemia risk during follow-up in relation with the existence of diabetes and/or renal failure (RF) at baseline visit.
STUDY DESIGN National multicentric prospective observational study that includes 12 months follow-up of consecutive cases of HF outpatients with REF. Inclusion baseline visit and follow -up visit at 12 months will be scheduled for collecting clinical and blood sample data of patients.
The study will be performed in ordinary conditions of clinical practice; no additional procedures or interventions will be performed. Patients will be selected in cardiology outpatient clinics of 20 Spanish centres, including the first 30 patients meeting inclusion and exclusion criteria. All patients will undergo the common studies according to usual clinical practice and at least both, potassium and renal creatinine clearance values will be collected.
To respond to the main objective, prevalence of hyperkalaemia at baseline will be determined as well as the appearance of new hyperkalaemia cases in the follow up of patients that had normal potassium levels at baseline visit; their relationship with outcomes of interest will also be determined
STUDY POPULATION:
The expected number of patients recruited in 20 Spanish research centres is 600.
CONSIDERATIONS ABOUT SIMPLE SIZE:
Assuming a 10% risk of outcomes (mortality or HF hospital admission) among the exposed (hyperkalaemia), 2.5% among the non-exposed and a 7:1 non-exposed/exposed ratio, 73 exposed and 511 non-exposed patients should be included to have a 80% power to detect these differences with a 95% confidence level. The recruitment goal is set at 600 patients.
This sample size allows a precision of ±2,4%, assuming a prevalence of hyperkalaemia at baseline of 10% and with a 95% confidence level. Furthermore, assuming 5% hyperkalaemia cumulative incidence through follow-up among hyperkalaemia-free patients at baseline, the proposed sample size, allows a precision of±1,8% with a 95% confidence level.
SELECTION OF CENTRES The number of participant centres throughout Spain will be 20 and a cardiologist will be the principal investigator at every centre. The centres have been selected either among those with excellence-certified HF units, included in CiberCV Consortium or with good performance in previous similar registries; this selection is not random, but based on interest and high performance criteria in the field of HF
VARIABLES AND CRF:
The main outcome variables are:
1. \- Hyperkalaemia. Serum Potassium (K+) will be measured in baseline and follow-up visits, but also if there is any intermediate hospital admission. All available potassium measurements during follow-up will be reviewed and values of hyperkalaemia identified. Hyperkalaemia will be considered with (K+) Values \> 5,4 mEq/L
2. \- Proportion of patients using drugs with proven efficacy for HF with REF -but also linked with hyperkalaemia- (ACEIs/ARB-II/ARNI and MRAs) and proportion of patients with use of optimal doses (based on current ESC heart failure guidelines2) of the same drugs; reason for not using them (or not receiving optimal doses) will be registered. Proportion of patients in the following categories will also be computed:
* No ACEi/ARB/ARNI or at less than target dose and no MRA
* ACEi/ARB/ARNI at target dose and no MRA
* ACEi/ARB/ARNI at target dose and MRA at less than target dose
* ACEi/ARB/ARNI at target dose and MRA at target dose
3. \- Hospital admissions during follow-up and main cause for them. Outcomes considered will include HF admissions caused by hyperkalaemia and related events. Outcome Serum (K+) values will be also registered.
4. \- Mortality and cause. HF (and hyperkalaemia) hospital admissions and mortality will be independently considered as outcomes; joint outcome incidence of both will be also calculated.
STUDY DEVELOPMENT:
Every participating centre will include from inclusion date the first 30 heart failure outpatients who fulfil the inclusion criteria and none of the exclusion ones. The excluded patients will be also registered, pointing out the reason of exclusion. A follow-up and final visit will be scheduled after 12 months for collecting all the variables the study requires. Hospitalisation data since inclusion visit will be also collected, together with the information of blood sample test performed in such period for detecting hyperkalaemia episodes. Mortality data will include date and cause, where possible. If follow-up visit cannot be conducted, the reason for it will be registered. The envisaged length of the study is 24 months since approval date.
DATA COLLECTION:
Consecutively, every researcher will handle and explain the information sheet to the patients that might fulfil de inclusion criteria (and do not present any exclusion criteria) and will ask them to sign the informed consent. Researchers must warrant the accuracy and completion of the data collected for the study. Data registered at CRF should be consistent with source documents used for their collection.
DATA MANAGEMENT:
Data will be collected during initial and follow-up visits and they will be integrated into a unique data base of the web platform. Researchers are responsible of the information included in the database and will access by means of personal login and password. The online platform will include ranges and rules to minimize errors in data registering.
PLAN FOR DATA ANALYSIS Hyperkalaemia prevalence at basal visit and the rate of patients who do not receive and/or reach optimal doses of drugs of interest (ACIEs, ARB-II, MRAs) will be estimated and their corresponding 95% confidence intervals computed. The reason for not receiving and/or reaching optimal doses of drugs will be described, especially if it is due to hyperkalaemia.
For those patients who do not present hyperkalaemia at baseline, 12 month hyperkalaemia cumulative incidence (95% confidence interval) will be estimated; also it will be estimated the proportion of patients who have to modify their therapy due to hyperkalaemia.
The number of episodes of hyperkalaemia during follow-up in relation to the number of patients will be estimated and their severity and the therapy changes that induced described. Also 12 months cumulative incidence of clinical outcomes will be estimated: hospitalisation due to HF or to, hyperkalaemia (and related events) and mortality, considered as individual and composite outcomes. The association between hyperkalaemia and occurrence of outcomes will be analyses and also adjusted using potential confounding factors by means of logistic regression models
The quantitative variables will be generally described using either the mean and the standard deviation or the median and interquartile range according them following or not a normal distribution. When comparing groups, t-student test will be used for continuous variables and chi-share test for qualitative ones.
Both, intermediate and final analysis, are planned to be carried out after baseline-visit closure and at the end of follow up (12 months).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Heart Failure With Reduced Ejection Fraction
Hyperkalemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heart failure (HF) outpatients with reduced ejection fraction
Heart Failure (HF) with reduced ejection fraction (REF): Patients with confirmed diagnosis of HF and with ejection fraction\<40%.
Hyperkalaemia: K+values\> 5,4 mEq/L.
Optimal doses: the maximum doses of renin-angiotensin-aldosterone related drugs that, according to the physician's judgement, the patient can receive. If any of these drugs (ACIEs, ARB-II, MRAs or sacubitril-valsartan) is de novointroducedat the initial visit, optimal doses will be not considered established.
A previous personal history of diseases and/or outcomes will be registered according to the usual practice of every centre.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients, women or men, aged 18 or more
2. Documented HF with REF (\<40%) diagnosis
3. Signed written informed consent
2. Documented HF with REF (\<40%) diagnosis
3. Signed written informed consent
Exclusion Criteria
1. Any type of disorder affecting the capacity to give free and informed written consent
2. Clinical trial enrolment at the moment of the inclusion
3. Patients suffering stage 5 chronic kidney disease
4. Patients with less than a year life span due to diseases different from HF
5. Not having completed HF drug titration stage at the moment of inclusion (this stage is not completed if, on doctor's judgement, possible maximum doses have not been reached in RAA system drugs and any of these drugs has been included or dose-modified in recruitment visit)
6. Informed consent refusal
At any time during follow-up patients can leave the study (and will be censored in the analysis) or retire their consent (and will be excluded from the analysis).
2. Clinical trial enrolment at the moment of the inclusion
3. Patients suffering stage 5 chronic kidney disease
4. Patients with less than a year life span due to diseases different from HF
5. Not having completed HF drug titration stage at the moment of inclusion (this stage is not completed if, on doctor's judgement, possible maximum doses have not been reached in RAA system drugs and any of these drugs has been included or dose-modified in recruitment visit)
6. Informed consent refusal
At any time during follow-up patients can leave the study (and will be censored in the analysis) or retire their consent (and will be excluded from the analysis).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Sponsor Role
collaborator
Spanish Society of Cardiology
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria G. Crespo Leiro
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
María G Crespo Leiro, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Complejo Hospitalario Universitario de A Coruña (CHUAC)
Juan Delgado Jiménez, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario 12 de Octubre, Madrid
Javier Muñiz García, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto Universitario de Ciencias da Saúde. Universidade da Coruña. INIBIC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario Universitario de A Coruña (CHUAC)
A Coruña, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Sayago-Silva I, Garcia-Lopez F, Segovia-Cubero J. Epidemiology of heart failure in Spain over the last 20 years. Rev Esp Cardiol (Engl Ed). 2013 Aug;66(8):649-56. doi: 10.1016/j.rec.2013.03.012. Epub 2013 Jul 5.
Reference Type
BACKGROUND
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. No abstract available.
Reference Type
BACKGROUND
WRITING COMMITTEE MEMBERS; Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5. No abstract available.
Reference Type
BACKGROUND
Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012 May 15;109(10):1510-3. doi: 10.1016/j.amjcard.2012.01.367. Epub 2012 Feb 18.
Reference Type
BACKGROUND
Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998 Apr 27;158(8):917-24. doi: 10.1001/archinte.158.8.917.
Reference Type
BACKGROUND
Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017 Jul 19;6(7):e005428. doi: 10.1161/JAHA.116.005428.
Reference Type
BACKGROUND
Sarwar CM, Papadimitriou L, Pitt B, Pina I, Zannad F, Anker SD, Gheorghiade M, Butler J. Hyperkalemia in Heart Failure. J Am Coll Cardiol. 2016 Oct 4;68(14):1575-89. doi: 10.1016/j.jacc.2016.06.060.
Reference Type
BACKGROUND
Crespo-Leiro MG, Segovia-Cubero J, Gonzalez-Costello J, Bayes-Genis A, Lopez-Fernandez S, Roig E, Sanz-Julve M, Fernandez-Vivancos C, de Mora-Martin M, Garcia-Pinilla JM, Varela-Roman A, Almenar-Bonet L, Lara-Padron A, de la Fuente-Galan L, Delgado-Jimenez J; project research team. Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry. Rev Esp Cardiol (Engl Ed). 2015 Sep;68(9):785-93. doi: 10.1016/j.rec.2015.03.008. Epub 2015 May 21.
Reference Type
BACKGROUND
Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, Minana G, Santas E, Chorro FJ, Mollar A, Carratala A, Navarro J, Gorriz JL, Lupon J, Husser O, Metra M, Sanchis J. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. Circulation. 2018 Mar 27;137(13):1320-1330. doi: 10.1161/CIRCULATIONAHA.117.030576. Epub 2017 Oct 12.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESR-17-13244
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Ambulatory Blood Pressure in HFPEF Outcomes Global Registry
NCT04065620
UNKNOWN
Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure
NCT00925470
COMPLETED
Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)
NCT03657875
COMPLETED
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00741585
COMPLETED
PHASE4
Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion
NCT00005204
COMPLETED
Study on Hypertension and Frailty in the Older People
NCT05776394
UNKNOWN
Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension
NCT03810443
UNKNOWN
NA
Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
NCT00004354
COMPLETED
Essential Hypotension and Allostasis Registry
NCT02018497
UNKNOWN
Target Organ Damage and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects
NCT02022618
COMPLETED
Primary Hyperaldosteronism and Ischemia-reperfusion Injury
NCT01978132
COMPLETED
NA
Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension
NCT07294794
NOT_YET_RECRUITING
NA
Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.
NCT04133428
UNKNOWN
HFR A-equilibrium on Cardiovascular Stability
NCT01414842
COMPLETED
PHASE4
Fifteen Year Follow-up of 5,500 Black and 5,500 Other Hypertensives
NCT00005417
COMPLETED
Resistant Arterial Hypertension Cohort Study
NCT01083017
COMPLETED
Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension
NCT01834118
COMPLETED
Evaluation of Target Organs Damage in Hypertensive Patients
NCT01055353
COMPLETED
The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis
NCT01703780
UNKNOWN
Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population
NCT00901355
COMPLETED
From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys
NCT05114291
COMPLETED
Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women
NCT00147524
COMPLETED
PHASE4
TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET IN PATIENTS WITH HTA
NCT04677322
TERMINATED